Program
Nifedipine
Also written as “Nifedipine (Adalat, BAYA1040)”, “Adalat (Nifedipine, BAYA1040)” and “Nifedipine Extended Release tablets 60 mg, single dose”.
Its studies are mostly in Hypertension · Essential Hypertension · Fissure in Ano · Diabetic Nephropathies, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 120 open or running | phase 4since Apr 16, 2008 | Apr 16, 2008 | none ahead |
| RDD Pharma | 20 open or running | phase 3since Aug 10, 2015 | Dec 11, 2013 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 1since Mar 18, 2009 | Mar 18, 2009 | none ahead |
| Reig Jofre Group | 10 open or running | phase 1since Dec 3, 2013 | Dec 3, 2013 | none ahead |
Also a collaborator on its studies: laboratorios-richmond-colombia-sas.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Apr 16, 2008.
- Sep 9, 2008Phase 4 study in HypertensionBayer · NCT00750113 · 405 enrolled · Italy, Spain
- Oct 7, 2008Phase 2 study in HypertensionBayer · NCT00768560 · 35 enrolled · Japan
- Mar 18, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00865891, NCT00864617
- Oct 9, 2009Phase 4 study in HypertensionBayer · NCT00993109 · 360 enrolled · China, Korea, Republic of
- Feb 18, 2010Phase 4 study in HypertensionBayer · NCT01071122 · 365 enrolled · Korea, Republic of
- Jan 30, 2011Phase 3 study in HypertensionBayer · NCT01287260 · 352 enrolled · Japan
- Feb 10, 2011Phase 3 study in HypertensionBayer · NCT01294215 · 72 enrolled · Japan
- Apr 18, 2011Phase 1 study in Essential HypertensionBayer · NCT01350609 · 49 enrolled · Germany
- Apr 21, 2011Phase 3 study in HypertensionBayer · NCT01355367 · 120 enrolled · Japan
- Jan 24, 2012Phase 4 study in HypertensionBayer · NCT01518855 · 514 enrolled · Japan
- Dec 3, 2013Reig Jofre Group's first study: phase 1 study in BioequivalenceNew to Reig Jofre GroupReig Jofre Group · NCT02071589 · 36 enrolled · Spain
- Dec 11, 2013RDD Pharma's first study: phase 2 study in Fissure in AnoNew to RDD PharmaRDD Pharma · NCT02023047 · 33 enrolled · Israel
- Apr 2, 2015Phase 4 study in HypertensionBayer · NCT02413515 · 278 enrolled · China
- Aug 10, 2015Phase 3 study in Chronic Anal FissureRDD Pharma · NCT02527109 · 339 enrolled · Bulgaria, Moldova, Republic of, Poland and more
TargetBeta
“Voltage-gated L-type calcium channel blocker”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Amlodipinerule | Novartis | phase 4 | 203 |
| Pregabalinrule | Viatris | phase 4 | 149 |
| Gabapentinrule | Viatris | phase 4 | 49 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT02527109Chronic Anal Fissure · Bulgaria, Moldova, Republic of, Poland and more | 3 | Completed | RDD Pharma | Jun 15, 2018 | 339 |
| NCT02413515Hypertension · China | 4 | Completed | Bayer | Aug 8, 2016 | 278 |
| NCT02023047Fissure in Ano · Israel | 2 | Terminated | RDD Pharma | Nov 2015 | 33 |
| NCT02071589Bioequivalence · Spain | 1 | Completed | Reig Jofre Group | Mar 2009 | 36 |
| NCT01518855Hypertension · Japan | 4 | Completed | Bayer | Apr 2005 | 514 |
| NCT01355367Hypertension · Japan | 3 | Completed | Bayer | Sep 2011 | 120 |
| NCT01350609Essential Hypertension · Germany | 1 | Completed | Bayer | Aug 2011 | 49 |
| NCT01294215Hypertension · Japan | 3 | Completed | Bayer | Nov 2011 | 72 |
| NCT01287260Hypertension · Japan | 3 | Completed | Bayer | Aug 2011 | 352 |
| NCT01071122Hypertension · Korea, Republic of | 4 | Completed | Bayer | Feb 2012 | 365 |
| NCT00993109Hypertension · China, Korea, Republic of | 4 | Completed | Bayer | May 2011 | 360 |
| NCT00865891Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jul 2005 | 96 |
| NCT00864617Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | May 2005 | 84 |
| NCT00768560Hypertension · Japan | 2 | Completed | Bayer | May 2008 | 35 |
| NCT00750113Hypertension · Italy, Spain | 4 | Completed | Bayer | Jul 2009 | 405 |
| NCT00713011Diabetic Nephropathies | 3 | Withdrawn | Bayer | Mar 2009 | 0 |
| NCT00672113Hypertension · United Kingdom | 4 | Completed | Bayer | 43 |
How it is read
Names in the registry
- “Nifedipine (Adalat, BAYA1040)”, 6 entries
- “Adalat (Nifedipine, BAYA1040)”, 2 entries
- “Nifedipine Extended Release tablets 60 mg, single dose”, 2 entries
- “Treatment with Nifedipine 30 mg Extended-Release (Richmond)”, 1 entry
- “Nifedipine”, 1 entry
Conditions, from the studies’ own filings
- Hypertension, 7 studies
- Essential Hypertension, 5 studies
- Fissure in Ano, 2 studies
- Diabetic Nephropathies, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.